ONCAlert | Upfront Therapy for mRCC

Rindopepimut for Recurrent Glioblastoma

David Reardon, MD
Published Online: 4:22 PM, Mon November 17, 2014
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.

Clinical Pearls

  • Rindopepimut (CDX-110) is a synthetic peptide vaccine designed to target the mutant epidermal growth factor receptor variant III.
  • This mutation drives tumor growth and is present in approximately 30% of glioblastoma tumors.
  • Rindopepimut sensitizes the immune system against this mutant receptor on glioblastoma tumor cells.

<<< View more from the 2014 SNO meeting

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.